Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1981 1
1994 1
1997 1
2000 1
2002 1
2008 11
2009 7
2010 9
2011 14
2012 11
2013 15
2014 20
2015 11
2016 6
2017 1
2018 1
2020 1
2021 1
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

104 results

Results by year

Filters applied: . Clear all
Page 1
Subacute myoclonic measles encephalitis - An opportunistic HIV-associated infection.
Ene L, Duiculescu D, Radoi R, Lazar M, Tardei G, Ungureanu E, Ruta S, Vinters HV, Letendre S, Grant I, Ellis RJ, Achim CL. Ene L, et al. Among authors: duiculescu d. Front Cell Neurosci. 2023 Apr 4;17:1113935. doi: 10.3389/fncel.2023.1113935. eCollection 2023. Front Cell Neurosci. 2023. PMID: 37082207 Free PMC article.
Healthcare delivery for HIV-positive people with tuberculosis in Europe.
Bentzon AK, Panteleev A, Mitsura V, Borodulina E, Skrahina A, Denisova E, Tetradov S, Podlasin R, Riekstina V, Kancauskiene Z, Paduto D, Mocroft A, Trofimova T, Miller R, Post F, Grezesczuk A, Lundgren JD, Inglot M, Podlekareva D, Bolokadze N, Kirk O; TB:HIV Study Group. Bentzon AK, et al. HIV Med. 2021 Apr;22(4):283-293. doi: 10.1111/hiv.13016. Epub 2020 Nov 20. HIV Med. 2021. PMID: 33215809 Free PMC article.
Prevalence and effect of pre-treatment drug resistance on the virological response to antiretroviral treatment initiated in HIV-infected children - a EuroCoord-CHAIN-EPPICC joint project.
Ngo-Giang-Huong N, Wittkop L, Judd A, Reiss P, Goetghebuer T, Duiculescu D, Noguera-Julian A, Marczynska M, Giacquinto C, Ene L, Ramos JT, Cellerai C, Klimkait T, Brichard B, Valerius N, Sabin C, Teira R, Obel N, Stephan C, de Wit S, Thorne C, Gibb D, Schwimmer C, Campbell MA, Pillay D, Lallemant M; EuroCoord-CHAIN-EPPICC joint project study group. Ngo-Giang-Huong N, et al. Among authors: duiculescu d. BMC Infect Dis. 2016 Nov 8;16(1):654. doi: 10.1186/s12879-016-1968-2. BMC Infect Dis. 2016. PMID: 27825316 Free PMC article.
Tuberculosis-related mortality in people living with HIV in Europe and Latin America: an international cohort study.
Podlekareva DN, Efsen AM, Schultze A, Post FA, Skrahina AM, Panteleev A, Furrer H, Miller RF, Losso MH, Toibaro J, Miro JM, Vassilenko A, Girardi E, Bruyand M, Obel N, Lundgren JD, Mocroft A, Kirk O; TB:HIV study group in EuroCoord. Podlekareva DN, et al. Lancet HIV. 2016 Mar;3(3):e120-31. doi: 10.1016/S2352-3018(15)00252-0. Epub 2016 Feb 2. Lancet HIV. 2016. PMID: 26939735 Free article.
Infection-related and -unrelated malignancies, HIV and the aging population.
Shepherd L, Borges Á, Ledergerber B, Domingo P, Castagna A, Rockstroh J, Knysz B, Tomazic J, Karpov I, Kirk O, Lundgren J, Mocroft A; EuroSIDA in EuroCOORD. Shepherd L, et al. HIV Med. 2016 Sep;17(8):590-600. doi: 10.1111/hiv.12359. Epub 2016 Feb 18. HIV Med. 2016. PMID: 26890156 Free article.
Tipranavir/Ritonavir (500/200 mg and 500/100 mg) Was Virologically Non-Inferior to Lopinavir/Ritonavir (400/100 mg) at Week 48 in Treatment-Naïve HIV-1-Infected Patients: A Randomized, Multinational, Multicenter Trial.
Cooper DA, Cordery DV, Zajdenverg R, Ruxrungtham K, Arastéh K, Bergmann F, Neto JL, Scherer J, Chaves RL, Robinson P; study team. Cooper DA, et al. PLoS One. 2016 Jan 5;11(1):e0144917. doi: 10.1371/journal.pone.0144917. eCollection 2016. PLoS One. 2016. PMID: 26730818 Free PMC article. Clinical Trial.
Once-daily dolutegravir versus darunavir plus ritonavir for treatment-naive adults with HIV-1 infection (FLAMINGO): 96 week results from a randomised, open-label, phase 3b study.
Molina JM, Clotet B, van Lunzen J, Lazzarin A, Cavassini M, Henry K, Kulagin V, Givens N, de Oliveira CF, Brennan C; FLAMINGO study team. Molina JM, et al. Lancet HIV. 2015 Apr;2(4):e127-36. doi: 10.1016/S2352-3018(15)00027-2. Epub 2015 Mar 10. Lancet HIV. 2015. PMID: 26424673 Clinical Trial.
104 results